Netris Pharma
LYON, FR· latest recorded location
NETRIS PHARMA is named on 4 US grants and 10 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 4
- Published applications
- 10
- Inventors
- 27
- Granted in 2026 so far
- 0
- Most recent grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 2 |
By publication year.
Technology areas
Share of 14 documents
Recent patents
- Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs10 Dec 2024US 12,162,932 B2
- Anti-netrin-1 antibody16 May 2023US 11,648,309 B2
- Anti-netrin-1 antibody3 Dec 2019US 10,494,427 B2
- Combined treatment with netrin-1 interfering drug and chemotherapeutic drug20 Feb 2018US 9,895,439 B2
- Novel Mcl-1 inhibitor and combination of Mcl-1 and a BH3 mimetic, such as a Bcl-2 inhibitor3 Jul 2025US 2025/0215071 A1
- Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs2 Jan 2025US 2025/0002572 A1
- Netrin-1 detection, companion test and therapy based on radiations17 Oct 2024US 2024/0342322 A1
- Anti-netrin-1 antibody to treat liver inflammation28 Sep 2023US 2023/0303676 A1
- Novel anti-netrin-1 antibody12 Mar 2020US 2020/0079842 A1
Most cited
By later US patents